Skip to main content

IQVIA Holdings Value Stock - Dividend - Research Selection

Iqvia s

ISIN: US46266C1053 , WKN: A2JSPM

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield%
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


IQVIA Holdings Inc.'s (NYSE:IQV) Intrinsic Value Is Potentially 64% Above Its Share Price

2024-07-04
Key Insights IQVIA Holdings' estimated fair value is US$339 based on 2 Stage Free Cash Flow to Equity IQVIA Holdings is...

Clinical Development Expertise Aids IQVIA (IQV), Costs High

2024-07-01
IQVIA (IQV) benefits from its healthcare-specific global IT infrastructure and domain expertise to expand and penetrate different markets.

Investors in IQVIA Holdings (NYSE:IQV) have seen respectable returns of 31% over the past five years

2024-06-30
It hasn't been the best quarter for IQVIA Holdings Inc. ( NYSE:IQV ) shareholders, since the share price has fallen 15...

Barclays Keeps Their Buy Rating on IQVIA Holdings (IQV)

2024-06-28
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Iqvia price target lowered by $20 at Barclays, here's why

2024-06-28
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

5 Analysts Assess IQVIA Hldgs: What You Need To Know

2024-06-28
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

IQVIA's SmartSolve eQMS Wins 2024 MedTech Breakthrough Award Best Use of Artificial Intelligence in Healthcare

2024-06-26
INNOVATION PARK - IQVIA , a leading global provider of AI-powered analytics, technology solutions, and clinical research services to the life sciences industry, today announced that the IQVIA...

Insiders At IQVIA Holdings Sold US$9.2m In Stock, Alluding To Potential Weakness

2024-06-25
In the last year, many IQVIA Holdings Inc. ( NYSE:IQV ) insiders sold a substantial stake in the company which may have...

IQVIA’s SmartSolve® eQMS Wins 2024 MedTech Breakthrough Award "Best Use of Artificial Intelligence in Healthcare"

2024-06-25
RESEARCH TRIANGLE PARK, N.C., June 25, 2024--IQVIA™ (NYSE:IQV), a leading global provider of AI-powered analytics, technology solutions, and clinical research services to the life sciences industry, today announced that the IQVIA SmartSolve Enterprise Quality Management System (eQMS) platform has been selected as the winner of the "Best Use of Artificial Intelligence in Healthcare" award in the 8th Annual MedTech Breakthrough Awards.

Goldman’s top 50 high Sharpe Ratio stocks

2024-06-25
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.